1. Home
  2. Labeler Index
  3. Mylan Institutional Inc.
  4. 51079-821
  5. Product Images: Levetiracetam

Product Images Levetiracetam

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 12 images provide visual information about the product associated with Levetiracetam NDC 51079-821 by Mylan Institutional Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Formula calculation for patients with renal impairment - a518c4f5 8b66 4770 b971 3534d581ca99 02

Formula calculation for patients with renal impairment - a518c4f5 8b66 4770 b971 3534d581ca99 02

This appears to be a formula or equation for calculating weight based on age, as well as a formula for calculating CLer (presumably some measure of renal function) based on gender. The last line appears to refer to a serum creatinine measurement, though it is unclear how it fits into the equations. Without additional context or explanation, the significance and proper use of this text is not available.*

Then CLcr is adjusted for body surface area (BSA) as follows - a518c4f5 8b66 4770 b971 3534d581ca99 03

Then CLcr is adjusted for body surface area (BSA) as follows - a518c4f5 8b66 4770 b971 3534d581ca99 03

Levetiracetam Structural Formula - a518c4f5 8b66 4770 b971 3534d581ca99 04

Levetiracetam Structural Formula - a518c4f5 8b66 4770 b971 3534d581ca99 04

Levetiracetam Oral Solution Weight-Based Dosing Calculation for Pediatric Patients - image 01

Levetiracetam Oral Solution Weight-Based Dosing Calculation for Pediatric Patients - image 01

Figure 1: Responder Rate (≥ 50% Reduction from Baseline) in Study 1 - image 02

Figure 1: Responder Rate (≥ 50% Reduction from Baseline) in Study 1 - image 02

Figure 2: Responder Rate (≥ 50% Reduction from Baseline) in Study 2: Period A - image 03

Figure 2: Responder Rate (≥ 50% Reduction from Baseline) in Study 2: Period A - image 03

Figure 3: Responder Rate (≥ 50% Reduction from Baseline) in Study 3 - image 04

Figure 3: Responder Rate (≥ 50% Reduction from Baseline) in Study 3 - image 04

The text describes statistical data related to the percentage of patients in a study. There are two percentages mentioned, 39.4% and 144%. The word "placebo" is mentioned along with the number 109, and a statement indicating that there was a statistically significant difference between the placebo and another group. More context is needed to fully understand the study and its results.*

Figure 4: Responder Rate (≥ 50% Reduction from Baseline) in Study 4 - image 05

Figure 4: Responder Rate (≥ 50% Reduction from Baseline) in Study 4 - image 05

This is a clinical trial or study in which the percentage of patients is presented. 44.6% has been highlighted and indicates that this percentage is significant compared to the placebo group, which had 19.6% of patients. The study had a sample size of 97 individuals in the placebo group.*

Figure 5: Responder Rate for All Patients Ages 1 Month to < 4 Years (≥ 50% Reduction from Baseline) in Study 5 - image 06

Figure 5: Responder Rate for All Patients Ages 1 Month to < 4 Years (≥ 50% Reduction from Baseline) in Study 5 - image 06

This is a report on statistics of a clinical trial. The percentage of improvement with respect to the treatment is 43.1%, while with the placebo it is 19.6%. A certain medication or placebo called "5 Leveraceam Tabis" was used in this trial. There was a statistically significant improvement observed with the medication compared to the placebo.*

Figure 6: Responder Rate (≥ 50% Reduction from Baseline) in PGTC Seizure Frequency per Week in Study 7 - image 07

Figure 6: Responder Rate (≥ 50% Reduction from Baseline) in PGTC Seizure Frequency per Week in Study 7 - image 07

Levetiracetam 500 mg Tablets Unit Carton Label - image 08

Levetiracetam 500 mg Tablets Unit Carton Label - image 08

This is a description of a medication called Levetiracetam, which comes in the form of tablets that are coated and contain 500mg of the active ingredient. The medication is only available with a prescription and comes in a bottle of 100 tablets. The usual dosage is not given but can be found in the accompanying prescription information and medication guide. The medication should be stored at room temperature between 20° to 25°C. It is manufactured by Mylan Pharmaceuticals Inc. and has an NDC code of 51079-821-20. It is a USP-controlled medication.*

Serialized Unit Carton - image 09

Serialized Unit Carton - image 09

This is a warning label on a drug package, indicating that the unit-dose packaging is not designed to be child-resistant and should be used only by adults in institutional settings. The label advises users to keep the medication out of the reach of children and notes that the container provides light-resistance. The package also includes a window displaying the lot number and expiration date. The brand of the medication is Mylan, and the company is located in Rockford, IL, USA. There is also a numerical code of 300000 107 present.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.